BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alkermes plc readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Alkermes plc's drugs run\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06843590-10854@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alixorexton: Phase 2 readout est. (NCT06843590)
DESCRIPTION:Alixorexton\, phase 2\, Idiopathic Hypersomnia.\nStudy: A Study
  to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Id
 iopathic Hypersomnia\nEstimated primary completion: November 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/alixorexton#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06843590
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455383-10854@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Alixorexton: Phase 3 readout est. (NCT07455383)
DESCRIPTION:Alixorexton\, phase 3\, Narcolepsy.\nStudy: A Study to Evaluate
  the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1\nEs
 timated primary completion: May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/alixorexton#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07455383
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502443-10854@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Alixorexton: Phase 3 readout est. (NCT07502443)
DESCRIPTION:Alixorexton\, phase 3\, Narcolepsy.\nStudy: A Study to Evaluate
  the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2\nEs
 timated primary completion: May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/alixorexton#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07502443
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540897-10854@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alixorexton: Phase 3 readout est. (NCT07540897)
DESCRIPTION:Alixorexton\, phase 3\, Narcolepsy.\nStudy: A Study to Evaluate
  the Efficacy\, Safety and Tolerability of ALKS 2680 in Adults With Narcol
 epsy Type 1 (Brilliance NT1 - 304)\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/alixorexton#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07540897
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04987229-9210@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olanzapine/samidorphan (Lybalvi): Phase 3 readout est. (NCT04987229
 )
DESCRIPTION:Olanzapine/samidorphan (Lybalvi)\, phase 3\, Schizophrenia.\nSt
 udy: Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/olanzapine-samidorphan-lybalvi#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04987229
URL:https://assetmemo.bio/drug/olanzapine-samidorphan-lybalvi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767683-10854@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Alixorexton: Phase 2/3 readout est. (NCT06767683)
DESCRIPTION:Alixorexton\, phase 2/3\, Narcolepsy.\nStudy: A Long-Term Study
  of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia\nEsti
 mated primary completion: June 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/alixorexton#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06767683
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483632-6976@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20340728
DTEND;VALUE=DATE:20340729
SUMMARY:Vumerity (Diroximel fumarate): Phase 3 readout est. (NCT07483632)
DESCRIPTION:Vumerity (Diroximel fumarate)\, phase 3\, Multiple Sclerosis.\n
 Study: A Study to Learn About the Safety of Diroximel Fumarate (DRF) and D
 imethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Particip
 ants With Relapsing Forms of Multiple Sclerosis (RMS)\nEstimated primary c
 ompletion: 28 July 2034. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/diroximel-fumarate#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07483632
URL:https://assetmemo.bio/drug/diroximel-fumarate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
